刺山柑异鼠李素通过抑制PI3K/AKT/mTOR信号通路保护软骨细胞外基质OA
Isorhamnetin from Capparis spinosa L.protects chondrocyte extracellular matrix by inhibiting the PI3K/AKT/mTOR signaling pathway
目的 骨关节炎(osteoarthritis,OA)作为一种全球高发的关节退变疾病,目前临床上仍缺乏能够有效延缓关节退行性病变的治疗手段.刺山柑(Capparis spinosa L.)是维吾尔医学中用于治疗风湿痹症的常用药材,在传统经验中显示出治疗OA的潜力,但其发挥疗效的具体活性物质及分子机制尚不清楚.因此,本研究旨在系统筛选刺山柑中抗OA的关键活性成分,并阐明其分子机制.方法 在网络药理学部分,①通过文献检索收集刺山柑的已知化学成分,并通过TCMSP与SwissADME平台筛选活性成分.②利用Swiss Target Prediction工具预测活性成分的潜在作用靶点后,将靶点与GeneCards、OMIM、TTD和DisGeNET数据库中OA相关基因取交集,获得共同靶点.③对共同靶点进行蛋白质互作(protein-protein interaction,PPI)网络分析和基因富集筛选枢纽靶点和关键通路.④运用分子对接技术对活性成分与枢纽靶点进行结合验证,从而锁定刺山柑的核心成分,并对核心成分进行专项网络药理学分析.在体外实验部分,通过CCK-8法确定药物的适宜作用浓度,使用IL-1β诱导ATDC5软骨细胞建立OA模型,采用甲苯胺蓝染色和蛋白免疫印迹(western blotting)评价细胞外基质代谢情况.最后,通过qPCR、western blotting和免疫荧光检测信号通路及细胞外基质代谢相关基因和蛋白的表达水平,并联合使用MK-2206与SC-79进行"挽救实验".采用GraphPad Prism 10.1.2软件进行统计分析,以P<0.05为差异具有统计学意义.结果 ①从刺山柑中筛选出33个活性成分,并鉴定出174个与OA相关的共同靶点.KEGG富集分析显示,PI3K-AKT信号通路显著富集.PPI网络分析显示,AKT1、TNF、IL6和BCL2被确定为关键枢纽靶点.分子对接结果表明,异鼠李素(isorhamnetin,ISO)与枢纽靶点之间的平均结合能负值最大,提示其可能是刺山柑治疗OA的关键成分.针对ISO的网络药理学分析进一步确认,AKT1处于核心节点位置,PI3K-AKT信号通路显著富集;且分子对接模拟揭示,ISO通过与AKT1的THR195/GLU191残基形成氢键、与LEU295/PHE161产生疏水作用而实现稳定结合.②ISO体外实验证实,60 μmol/L浓度的ISO在提升软骨细胞活力的同时未表现毒性;该浓度能显著逆转IL-1β诱导的细胞外基质降解,使Ⅱ型胶原蛋白表达明显上升,同时显著降低MMP13的表达水平(P均<0.01).在机制层面,ISO处理抑制了IL-1β引起的PI3K、AKT及mTOR的过度活化,并通过"挽救实验"最终确立了PI3K/AKT/mTOR通路的核心作用:AKT抑制剂MK-2206可协同增强ISO对上述通路的抑制和对细胞外基质的保护作用;相 反,AKT激动剂SC-79则拮抗了ISO所带来的保护作用(P均<0.01).结论 本研究结果表明,ISO是刺山柑中发挥抗OA作用的关键成分,可能通过抑制PI3K/AKT/mTOR信号通路治疗OA.
Objective Osteoarthritis(OA),a highly prevalent degenerative joint disease worldwide,still lacks effective clinical treatments capable of delaying the progression of joint degeneration at present.Capparis spinosa L.is a commonly used herb in Uyghur medicine for the treatment of rheumatic arthralgia,has shown its therapeutic potential for OA in traditional clinical practice.However,the specific active substances responsible for its efficacy and the underlying molecular mechanisms remain unclear.Therefore,this study aims to systematically screen the key active components of Capparis spinosa L.against OA and elucidate their underlying molecular mechanisms.Methods In the network pharmacology section,① the known chemical components of Capparis spinosa L.were collected through literature retrieval,and the active components were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and SwissADME web tools.② The potential targets of the active components were predicted using SwissTargetPrediction,and these targets were intersected with OA-related genes from the GeneCards,Online Mendelian Inheritance in Man(OMIM),Therapeutic Target Database(TTD)and DisGeNET databases to obtain common targets.③ Protein-protein interaction(PPI)network analysis and gene enrichment analysis were performed on the common targets to screen hub targets and key signaling pathways.④ Molecular docking was then applied to validate the binding affinity between the active components and hub targets,thereby locking the core component of Capparis spinosa L.,followed by a specific network pharmacology analysis of the core component.In the in vitro experimental section,the appropriate working concentration of the drug was determined by CCK-8 assay.A cellular model of OA was established by IL-1β-induced ATDC5 chondrocytes.Toluidine blue staining and Western blotting were used to evaluate the metabolism of the extracellular matrix(ECM).Finally,qPCR,Western blotting and immunofluorescence staining were performed to detect the expression levels of genes and proteins related to the signaling pathway and ECM metabolism,and a"rescue experiment"was conducted using Akt inhibitor MK-2206 and its activator SC-79 in combination with the target drug.Statistical analysis was performed using GraphPad Prism 10.1.2,with P<0.05 considered statistically significant.Results ① A total of 33 active components were screened from Capparis spinosa L.,and 174 OA-related common targets were identified.KEGG enrichment analysis revealed significant enrichment of the PI3K-AKT signaling pathway.PPI network analysis identified AKT1,TNF,IL6 and BCL2 as key hub targets.Molecular docking results indicated that isorhamnetin(ISO)exhibited the greatest average negative binding energy with the hub targets,suggesting that it may be the key component of Capparis spinosa L.in the treatment of OA.Network pharmacology analysis targeting ISO further confirmed that AKT1 was at the core node position,with the PI3K-AKT signaling pathway significantly enriched.Molecular docking simulation revealed that ISO achieved stable binding with AKT1 by forming hydrogen bonds with the THR195 and GLU191 residues of AKT1,as well as through hydrophobic interactions with its LEU295 and PHE161 residues.② In vitro experiments confirmed that ISO at a concentration of 60 μmol/L enhanced chondrocyte viability without exhibiting cytotoxicity.This concentration significantly reversed IL-1β-induced ECM degradation,markedly upregulated the expression of type Ⅱ collagen,and simultaneously reduced the expression level of matrix metalloproteinase 13(MMP13)(all P<0.01).At the mechanistic level,ISO treatment inhibited the overactivation of PI3K,AKT and mTOR induced by IL-1β.The rescue experiment ultimately established the core role of the PI3K/AKT/mTOR signaling pathway:the AKT inhibitor MK-2206 synergistically enhanced the inhibitory effect of ISO on the aforementioned pathway and its protective effect on the ECM;conversely,the AKT activator SC-79 antagonized the protective effect of ISO(all P<0.01).Conclusion Our results demonstrate that ISO is the key active component of Capparis spinosa L.showing anti-OA effects,and it may exert a therapeutic effect on OA by inhibiting the PI3K/AKT/mTOR signaling pathway.
翁文豪;王维山;盛刚刚;任宣臣;杨子敬;郭泽凡;马涛;李超鹏;庞楠楠;张振东
石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子石河子大学第一附属医院临床学院,新疆石河子
医药卫生
骨关节炎刺山柑异鼠李素PI3K/AKT/mTOR通路网络药理学
osteoarthritisCapparis spinosa L.isorhamnetinPI3K/AKT/mTOR pathwaynetwork pharmacology
《陆军军医大学学报》 2026 (12)
1692-1702,11
TGFβ1调控MCP1诱导BMSCs迁移在血管钙化并骨质疏松病变中的机制研究,国家自然基金地区科学基金项目(82160423)人工智能辅助骨关节炎精准诊疗体系的研究、建立和应用示范,兵团重点研发计划(2025AA002)SIRT3通过AMPK信号通路抑制软骨细胞铁死亡延缓OA软骨退变的机制研究,兵团科技计划项目(2024DA042) Supported by the Regional Science Fund Program of National Natural Science Foundation of China(82160423),the Major Science and Technology Project of Xinjiang Production and Construction Corps(2025AA002),and the Project of Natural Science Support Program of Xinjiang Production and Construction Corps(2024DA042).
评论